Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | TACR1 | P25103 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10112073 | 1.00 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL21239569 | 0.89 | TSHR (0.56) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL22431748 | 0.85 | TSHR (0.44) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL22431708 | 0.84 | AGXT (0.41) | CA1CA2CA9TACR1KMT2A | |
| SCHEMBL19750824 | 0.84 | TSHR (0.47) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL10127440 | 0.84 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL12444919 | 0.84 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL12444920 | 0.84 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL10112095 | 0.83 | HTT (0.46) | TSHRCA1CA2CA9KMT2A | |
| SCHEMBL12153280 | 0.83 | HTT (0.46) | TSHRCA1CA2CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170354636-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | SEQUOIA PHARMACEUTICALS INC (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354636-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | HCCS, CYP2E1, CYP7A1 | TSHR 3887/4885CA1 2740/4885CA2 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.